Memorial Sloan Kettering Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Memorial Sloan Kettering Cancer Center sits in the top decile of US sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count).
Memorial Sloan Kettering Cancer Center: 1,884 sponsored US clinical trials, 327 recruiting.
Memorial Sloan Kettering Cancer Center sponsors 1,884 registered US clinical trials on ClinicalTrials.gov, 327 of them currently recruiting, and 1,104 completed. 75 of these trials are in Phase 3-4 (later-stage) and 1,101 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 98 trials.
Top-decile sponsor footprint
Memorial Sloan Kettering Cancer Center ranks in the top decile of sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
1,884 total, page 24 of 38
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
NCT01404949
Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer
NCT01386411
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
NCT01383759
Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors
NCT01379287
Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others
NCT01392222
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
NCT01351623
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma
NCT01356251
Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid
NCT01349647
A Single Center Randomized Controlled Trial Assessing Pain and Quality of Life Following Surgery
NCT01355926
Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer
NCT01354951
Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer
NCT01345175
Tobacco-Focused Patient Navigation to Address Barriers to Utilization of Community-Based Smoking Cessation Services in Primary Care
NCT01678118
Trial of Individual Psychosocial Interventions for Cancer Patients
NCT01323309
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer
NCT01312857
Telemedicine Evaluation for Stem Cell Transplant Patients
NCT01324427
Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)
NCT01393483
Quit IT: Development of a Web-based, 3D Coping Skills Game to Increase Self-Efficacy for Maintaining Smoking Abstinence Following Hospitalization
NCT01915836
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
NCT01297452
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
NCT01294670
Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus
NCT01300429
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
NCT01323517
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
NCT01276041
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
NCT01273896
Therapy for Erectile Dysfunction Adaptation of ACT for Compliance With an Erectile Rehabilitation Program
NCT01275404
Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma
NCT01268579
Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive
NCT01262040
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma
NCT01261728
Aerobic Training in Metastatic Breast Cancer
NCT01725633
Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events
NCT01262222
RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder
NCT01259063
Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation
NCT01253590
Trial Comparing the Effects of Linear Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer
NCT01186367
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
NCT01248962
Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission
NCT01248273
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
NCT01252251
Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast
NCT01249157
GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy
NCT01239251
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab
NCT01223235
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
NCT01209598
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
NCT01200355
Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers
NCT01213004
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
NCT01183429
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
NCT01183897
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation
NCT01183416
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
NCT01183065
Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life
NCT01181648
Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies
NCT01182168
Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites
NCT01188746
Lung Inflammation and Lung Metastases From Breast Cancer
NCT01182519
Characterization of Rectal Cancer Hypoxia Using pO2 Histography and Immunohistochemistry for Hypoxia-Related Proteins
NCT01189877
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 461 |
| Phase 2 | 640 |
| Phase 3 | 67 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the Memorial Sloan Kettering Cancer Center pipeline
327 recruiting of 1,884 indexed (17% open); 1,104 completed (59%).
Phase mix: 75 late (III/IV) vs 1,101 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (98 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.